Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Aegera Therapeutics, Inc.

Home Clinical Trial Sponsors and OrganizationsAegera Therapeutics, Inc.

Aegera Therapeutics, Inc.

ACTIVE

Canadawww.aegera.comSubsidiary11–50 employeesEstablished: 1997-01-01

Part of pharmasciences, inc.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

3

3 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1997

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

1

33.3%

Trial Status Distribution

Active, not recruiting

3

100.0%

Clinical Trials

Trials sponsored by this organization (3)

An Open-Label Randomized Phase 2 Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen.

Active, not recruiting

Oct 200960 participants

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 versus Placebo in Patients with Painful Diabetic Peripheral Neuropathy - n/a

Active, not recruiting

Jul 2009128 participants

A Phase 1-2, Multicenter, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer

Active, not recruiting

Feb 200840 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials3
Approvals
News

Back to Organizations